BRISTOL MYERS SQUIBB CO - 10-Q Filing
Bristol Myers Squibb reports Q3 2026 financial results including product sales and R&D expenditure details.
Tickers: $BMY
Read the full article at SEC EDGAR
Part of the story Bristol Myers Squibb Q3 Revenue Grows 7% Driven by Expanding Growth Drug Portfolio (3 articles)